Identifai Genetics is developing a noninvasive prenatal test for the early detection of single-gene disorders. Using a simple first-trimester maternal blood test to access the entire embryonic genome, Identifai can perform a comprehensive analysis capable of detecting every single-point mutation, insertion-deletion, and structural variation in order to identify severe genetic disorders. Identifais core suite of algorithms, the Hoobari paradigm, is a patent-pending proprietary methodology developed for five years at Tel Aviv University. The technology has demonstrated high accuracy in detecting a wide variety of mutations in real-life cases, and the company is planning to launch clinical studies. Identifai Genetics is dedicated to providing solutions that will enable safe pregnancies for all families, everywhere.